/SNG.L

SNG.L Stock - Synairgen plc

Q: What is the analyst price target for SNG.L?

Analyst price target information is not currently available for SNG.L.

Q: What is SNG.L's market cap?

Market capitalization information is not currently available for SNG.L.

Healthcare|Biotechnology|LSE

$0.95+0.00%

+$0.00 (+0.00%) • Apr 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.04

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SNG.L

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-2.12

52W High$10.00

52W Low$0.60

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-84,000	$-102,000	$-195,000	$-260,000	$-163,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-10,292,000	$-20,300,000	$-57,866,000	$-17,741,000	$-4,817,000
Net Income	$-8,408,000	$-17,645,000	$-48,663,000	$-13,916,000	$-3,885,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.04	$-0.09	$-0.24	$-0.09	$-0.04

Company Overview

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Visit Website

Earnings History & Surprises

SNG.L

Beat Rate

Last 1 quarters

Avg Surprise

-10.2%

EPS vs Estimate

Beats / Misses

0/1

Last 12 quarters

Latest EPS

$-0.02

Q3 2024

EPS Surprise History

Q4 20

No data

Q2 21

No data

Q4 21

No data

Q2 22

No data

Q2 23

No data

Q3 23

-10.2%

$-0.02vs$-0.02

Q2 24

No data

Q3 24

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	Jun 25, 2025	—	—	—	—
Q3 2024	Sep 26, 2024	—	$-0.02	—	—
Q2 2024	Jun 27, 2024	—	$-0.00	—	—
Q3 2023	Sep 21, 2023	$-0.02	$-0.02	-10.2%	✗ MISS
Q2 2023	Apr 27, 2023	—	$-0.03	—	—
Q2 2022	Jun 30, 2022	—	$-0.06	—	—
Q4 2021	Dec 31, 2021	—	$-0.08	—	—
Q2 2021	Jun 30, 2021	—	$-0.16	—	—
Q4 2020	Dec 31, 2020	—	$-0.06	—	—
Q2 2020	Jun 30, 2020	—	$-0.03	—	—
Q4 2019	Dec 31, 2019	—	$-0.02	—	—
Q2 2019	Jun 30, 2019	—	$-0.02	—	—
Q4 2018	Dec 31, 2018	—	$-0.00	—	—
Q2 2018	Jun 30, 2018	—	$-0.00	—	—
Q4 2017	Dec 31, 2017	—	$0.00	—	—
Q2 2017	Jun 30, 2017	—	$-0.00	—	—
Q4 2016	Dec 31, 2016	—	$-0.00	—	—
Q2 2016	Jun 30, 2016	—	$-0.00	—	—
Q4 2015	Dec 31, 2015	—	$-0.00	—	—
Q2 2015	Jun 30, 2015	—	$-0.00	—	—